BioCentury | Apr 19, 2019
Clinical News

LineaRx produces CAR T cells via non-viral, plasmid-free platform

...CAR T therapy LinCART19. LineaRx is a subsidiary of Applied DNA Sciences Inc. (NASDAQ:APDN). Mary Romeo, Staff Writer Applied DNA Sciences Inc. LineaRx...
BioCentury | Oct 26, 2017
Tools & Techniques

Ripe for enhancement

Although still largely the purview of academics, technologies for mapping enhancers to the genes they control are rapidly gaining efficiency and promise to unlock a trove of new targets for drug developers. But companies will...
BioCentury | Aug 18, 2017
Translation in Brief

Next-generation growth spurt

A milestone FDA approval could signal next-generation sequencing tests are on the verge of becoming established players in cancer diagnostics. A series of papers published this week highlights further advances in NGS technology, but the...
BioCentury | Jul 9, 2015
Strategy

GSK aims higher in genetics

GlaxoSmithKline plc 's launch of the independent Altius Institute for Biomedical Sciences last month showed the pharma is making the use of cutting-edge research and technologies for gene regulation a top priority in guiding its...
BioCentury | Nov 6, 2006
Company News

Odyssey board of directors update

...Odyssey Thera Inc. , San Ramon, Calif. Business: Cancer Appointed: Hugh Rienhoff, former CEO of DNA Sciences Inc. WIR...
BioCentury | Oct 19, 2004
Company News

NeoRx names Berland CFO

...as CFO. Most recently, Berland served as an industry consultant. She previously was CFO of DNA Sciences...
BioCentury | May 3, 2004
Company News

Genaissance, University of Utah, Yale University deal

...third parties for use in research. GNSC acquired the license through its 2003 acquisition of DNA Sciences Inc....
BioCentury | Mar 1, 2004
Company News

Lynx management update

...Proteomics Departed: Edward Albini as CFO Hired: Susan Berland as interim CFO, formerly CFO at DNA Sciences Inc. WIR...
BioCentury | Apr 7, 2003
Company News

DNA Sciences, Genaissance deal

...GNSC will acquire the assets of DNA Sciences for $1.3 million in cash and stock. DNA Sciences, which...
...to its pharmacogenomics program. GNSC expects the deal to be cash flow positive in 2004. DNA Sciences Inc....
BioCentury | Apr 1, 2003
Company News

GNSC to acquire DNA Sciences' assets

...will acquire the assets of DNA Sciences (Fremont, Calif.) for $1.3 million in cash and stock. DNA Sciences...
Items per page:
1 - 10 of 55
BioCentury | Apr 19, 2019
Clinical News

LineaRx produces CAR T cells via non-viral, plasmid-free platform

...CAR T therapy LinCART19. LineaRx is a subsidiary of Applied DNA Sciences Inc. (NASDAQ:APDN). Mary Romeo, Staff Writer Applied DNA Sciences Inc. LineaRx...
BioCentury | Oct 26, 2017
Tools & Techniques

Ripe for enhancement

Although still largely the purview of academics, technologies for mapping enhancers to the genes they control are rapidly gaining efficiency and promise to unlock a trove of new targets for drug developers. But companies will...
BioCentury | Aug 18, 2017
Translation in Brief

Next-generation growth spurt

A milestone FDA approval could signal next-generation sequencing tests are on the verge of becoming established players in cancer diagnostics. A series of papers published this week highlights further advances in NGS technology, but the...
BioCentury | Jul 9, 2015
Strategy

GSK aims higher in genetics

GlaxoSmithKline plc 's launch of the independent Altius Institute for Biomedical Sciences last month showed the pharma is making the use of cutting-edge research and technologies for gene regulation a top priority in guiding its...
BioCentury | Nov 6, 2006
Company News

Odyssey board of directors update

...Odyssey Thera Inc. , San Ramon, Calif. Business: Cancer Appointed: Hugh Rienhoff, former CEO of DNA Sciences Inc. WIR...
BioCentury | Oct 19, 2004
Company News

NeoRx names Berland CFO

...as CFO. Most recently, Berland served as an industry consultant. She previously was CFO of DNA Sciences...
BioCentury | May 3, 2004
Company News

Genaissance, University of Utah, Yale University deal

...third parties for use in research. GNSC acquired the license through its 2003 acquisition of DNA Sciences Inc....
BioCentury | Mar 1, 2004
Company News

Lynx management update

...Proteomics Departed: Edward Albini as CFO Hired: Susan Berland as interim CFO, formerly CFO at DNA Sciences Inc. WIR...
BioCentury | Apr 7, 2003
Company News

DNA Sciences, Genaissance deal

...GNSC will acquire the assets of DNA Sciences for $1.3 million in cash and stock. DNA Sciences, which...
...to its pharmacogenomics program. GNSC expects the deal to be cash flow positive in 2004. DNA Sciences Inc....
BioCentury | Apr 1, 2003
Company News

GNSC to acquire DNA Sciences' assets

...will acquire the assets of DNA Sciences (Fremont, Calif.) for $1.3 million in cash and stock. DNA Sciences...
Items per page:
1 - 10 of 55